Cas no.123663-49-0

Formula

Seres Product Name: Ellamod

Seres alias: N [3 (Carboxamido) -4-Oxo-VI-phenoxy-4h-I-Benzopyran-VII-YL] Methanesulfonamide

Latina Product Name: iguratimod

CAS # 123663-49-0

Molecular formula: c17h14n2o6s

Molecular pondus: 374,3679

Specie et proprietates alba pulveris

Domesticis Registration Number API: Y20190021542

Cas No.123663-49-0 est pro anti-RHEUMATICUS medicamento, Synovitis medicamento.

Chemical proprietatibus et structuram Analysis

In componit correspondentes CAS 123663-49-0 potest esse nitrogenous heterocyclic derivationes cum M. Molecular pondus circiter 280-320 G / Mol, chiral centrum et aromaticum anulum structuram. Infrarubrum spectris ostendit effusio peaks primaria Amine Group (-nh2) et carbonyl Group (c = o). Multiplex iugis in Δ7.2-8.5ppm range of hydrogenii NMR Spectra suggesserant benzene annulum substitutionem. Substantia est album crystallina pulveris ad locus temperatus, liquescens punctum range 128-132 ℃, facile solutum in Suspendisse solvents ut DMF, logp value 2.3 ostendit modica lipophilicity.

Core applications in agro medicina

Ut a key pharmaceutical medium, cas 123663-49-0 est late in synthesis de Tyrosine Kinase inhibitors. Praeclinical studia ostendit quod IC50 valorem de derivativa contra EGFR, mutant pulmone cancer cellula lineae pervenit 12nm, quod erat VIII temporibus magis activae quam primam generationem inhibitor. In MMXXII Internationalis annua conventu de medicinalibus, moderna detectus quod oris anticancer medicamento developed usura is medium est ingressus tempus II orci iudiciis cum bioavailability de LXVII%.

Industrial Synthesis Processus

The industrial production of 123663-49-0 adopts a modular synthesis strategy: 4-chlorophenone is used as the starting material, the key C-N bond is constructed by Buchwald-Hartwig amination reaction, and the pyrimidine ring is introduced by palladium-catalyzed cross-coupling. Post processus optimization, summa cede ex tribus-gradum reactionem est auctus a XXXII% ad LVIII% et catalyst onus reducitur ad 0.5Mol%. Est dignum attendens quod Cas numeri substantia necessitates ad capere gradientis crystallization modum in purificationem scaena ut isomer puritate> 99.5%.

Salus et obsequium procuratio

Secundum GHS genus, CAS 123663-49-0 est classificatis sicut acutus toxicity genus IV (oris ld50 = 1200mg / kg) et requirit classis B tutela apparatu ut fertur in operationem. EU ad procuratio requirit ad repono temperatus ut stricte regi 2-8 ° C ad vitare lux degradation ad producendum nitro per-products. Msds documentis specie monere, ut contactus cum fortis oxidants et dimittere altus toxicus hydrogenium cyanide Gas, et subitis curatio debet instructi X% sodium thiosulfate solution.

Market Spes et Patentibus layout

In global foro demanda pro 123663-49-0 est crescente ad an mediocris annua rate of 14.7%, et in foro mole est aestimari ad pervenire $ CCXXX million in MMXXIII. In Donentium Donentem Tenuit per Pfizer Covers Crystallina Modus Cas, et in Donentis Donentem Donec Donentia. A Casyticum Creatica System PHARMACEUTICICAL societates habere feliciter circumveniebant originale patents, reducitur productio costs per XL%, quod nunc propter XXXII% de global supplementum catenam.

Notandum est maxime quod in specifica notitia circa CAS 123663-49-0 potest habere commercial secreto angustiis et ipsam applicationem erit subiectum ad auctoritatem database vel technica documenta provisum est a elit. Est commendatur ut reprehendo in tardus investigationis progressus per sciffinder aut REXYS Platform, et Stricte deducendi EHS Management Ratio in Industrial Applications. In speciali valorem huius casuum substantiam reflectitur in modifiability de eius mycecula structuram, faciens eam a key aedificium obstructionum pro innovative medicamento progressionem.